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Highlights 
 
 
 
 Age and cardiovascular conditions initiate cerebral hypoperfusion 
 
 Chronic cerebral hypoperfusion (CCH) causes blood-brain barrier (BBB) dysfunction  
 
 BBB dysfunction causes oxidative stress, inflammation, and mitochondrial dysfunction 
 
 BBB dysfunction mediates a vicious circle causing CCH aggravation and neuronal damage 
 
 BBB dysfunction is worsened by Aβ-endothelium interaction 
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Abstract 
 
Late-onset dementia is a major health concern in the aging population. Alzheimer’s disease (AD) ac-
counts for the largest proportion (65-70%) of dementia cases in the older population. 
Despite considerable research effort, the pathogenesis of late-onset AD remains unclear. Substantial 
evidence suggests that the neurodegenerative process is initiated by chronic cerebral hypoperfusion 
(CCH) caused by aging and cardiovascular conditions. CCH causes reduced oxygen, glucose and oth-
er nutrient supply to the brain, with direct damage not only to parenchymal cells, but also to the 
blood-brain barrier (BBB), a key mediator of cerebral homeostasis. BBB dysfunction mediates the 
indirect neurotoxic effects of CCH by promoting oxidative stress, inflammation, paracellular permea-
bility, and dysregulation of nitric oxide, a key regulator of regional blood flow. As such, BBB dys-
function mediates a vicious circle in which cerebral perfusion is reduced further and the neurodegen-
erative process is accelerated. Endothelial interaction with pericytes and astrocytes could also play a 
role in the process. Reciprocal interactions between vascular dysfunction and neurodegeneration 
could further contribute to the development of the disease. 
A comprehensive overview of the complex scenario of interacting endothelium-mediated processes is 
currently lacking, and could prospectively contribute to the identification of adequate therapeutic in-
terventions.  
This study reviews the current literature of in vitro and ex vivo studies on endothelium-mediated 
mechanisms underlying vascular dysfunction in AD pathogenesis, with the aim of presenting a com-
prehensive overview of the complex network of causative relationships. Particular emphasis is given 
to vicious circles which can accelerate the process of neurovascular degeneration. 
 
 
Keywords: Alzheimer’s disease; blood-brain barrier permeability; cerebral hypoperfusion; endotheli-
al dysfunction; mitochondrial dysfunction; ultrastructural damage  
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1. Introduction 
 
Late-onset dementia – an irreversible and debilitating condition characterized by progressive cogni-
tive decline – is a major health concern in the aging population. Alzheimer’s disease (AD) accounts 
for the largest proportion (65-70%) of dementia cases in the older population [1–3]. Despite consider-
able research effort, the pathogenesis of sporadic AD remains unclear. A longstanding hypothesis 
proposed by Hardy and Higgins [4] – known as the “amyloid cascade hypothesis” – suggests that AD 
pathology is initiated by the deposition of insoluble amyloid β (Aβ) fragments resulting from amyloid 
precursor protein (AβPP) proteolysis. An imbalance between Aβ production and clearance results in 
toxic Aβ concentrations, neuronal tau protein hyperphosphorylation and consequent neurofibrillary 
tangle formation [5]. However, substantial evidence [6–10] suggests that the neurodegenerative pro-
cess is initiated by chronic cerebral hypoperfusion caused by aging, vascular conditions such as hy-
pertension, atherosclerosis, type II diabetes, hypercholesterolemia [6, 8–11], and possibly cardiac 
conditions such as atrial fibrillation and chronic heart failure [7, 12, 13]. Chronic hypoperfusion caus-
es reduced oxygen, glucose and other nutrient supply to the brain [14], with direct damage not only to 
parenchymal cells, but also to the blood-brain barrier (BBB), a key mediator of cerebral homeostasis. 
BBB dysfunction mediates the indirect neurotoxic effects of chronic hypoperfusion by promoting ox-
idative stress [6, 15, 16], inflammation [17–20], impaired glucose transport across the BBB [21–23], 
BBB permeability [21, 24, 25], and dysregulation of nitric oxide (NO) [26–28], a key mediator of 
vascular tone and regional blood flow regulation [29, 30]. As such, BBB dysfunction could mediate a 
vicious circle in which cerebral perfusion is reduced further and the neurodegenerative process is ac-
celerated [31–33]. Adjacent to endothelial cells, astrocytes and pericytes could also play a role in this 
process. Indeed, astrocytes are known to amplify the endothelial response during inflammation [34, 
35], and some studies suggest that pericytes could contribute to microvascular tone regulation and 
regional blood flow distribution [36–38]. Reciprocal interactions between vascular dysfunction and 
neurodegeneration have also been proposed [39, 40], supported by a large body of in vitro evidence of 
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oligomeric Aβ interaction with endothelial [41–46] and smooth muscle cells [47, 48], and by post 
mortem studies showing coexisting cerebrovascular disease in most AD patients [6, 49–51].  
Neurofibrillary tangles (NFT), a characteristic hallmark of AD together with senile plaques, have also 
been proposed to originate from chronic cerebral hypoperfusion [52], although manifesting in the later 
stage of AD progression [53]. However, there is limited quantitative evidence of a direct link between 
microvascular dysfunction and NFT formation, and microvascular abnormalities appear to correlate to 
Aβ deposition rather than neurofibrillary tangles [54, 55]. 
As early elements which could precede the clinical manifestation of AD by years or even decades 
[56–59], chronic cerebral hypoperfusion and BBB dysfunction emerge as a crucial topic of investiga-
tion, with prospective potential for therapeutic intervention. 
 
1.1 Review focus 
 
The endothelium-mediated processes implicated in the vascular component of AD pathogenesis inter-
act in a complex network of cause-effect relationships. A comprehensive overview of this network is 
currently lacking, and could prospectively contribute to the identification of adequate therapeutic in-
terventions.  
This study reviews the current literature of in vitro and ex vivo studies on endothelium-mediated 
mechanisms underlying vascular dysfunction in AD pathogenesis (sections 2-4), with the aim of pre-
senting a comprehensive overview of the network of causative relationships (section 5). Particular 
emphasis is given to mediators of detrimental vicious circles, such as hypoxia/ischemia, oxidative 
stress, inflammation and mitochondrial dysfunction. The potential role of pericytes and astrocytes in 
this complex scenario is also investigated. 
 
2. BBB dysfunction in AD 
 
In the cerebral circulation, the BBB is a highly specialized structure which maintains neuronal home-
ostasis by regulating the flux of electrolytes, metabolites, toxic molecules, xenobiotics, and circulating 
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immune cells between the bloodstream and the brain parenchyma [60, 61]. The BBB is formed by the 
capillary endothelium, the basement membrane, and the surrounding pericytes and astrocyte end-feet. 
The endothelial cells of the BBB adhere to one another through junctional structures, termed tight 
(TJ) and adherens junctions, which regulate paracellular permeability (the so-called ‘gate function’), 
and maintain the polarity of enzymes and receptors on the luminal and abluminal domains of the en-
dothelial membrane (‘fence function’) [34, 62]. Small lipid-soluble molecules, such as oxygen, car-
bon-dioxide, and typical therapeutic drugs, can diffuse freely across the BBB [63], whereas the ex-
change of larger molecules occurs by active transport (transcytosis) through the cell body or by para-
cellular transport [9, 64]. 
In AD, the BBB undergoes functional and structural changes which disrupt the gate function, impair 
energy supply to the brain, reduce the clearance of Aβ, and produce neurotoxic molecules. Due to its 
central role in cerebral homeostasis, the BBB becomes both a target and source of injury in the devel-
opment of the disease.     
 
2.1 Impaired glucose transport  
 
Glucose – the main energy source for the brain – requires a carrier (transporter) to cross the BBB. In 
the human BBB, this is mainly achieved by glucose transporter 1 (GLUT-1).  
Glucose uptake in the brain is determined by the concentration of glucose in the plasma, as well as the 
concentration of GLUT transporters in the BBB. Positron emission tomography (PET) studies have 
demonstrated reduced regional metabolic rate in the AD brain, especially in temporal and parietal cor-
tical regions [65–68]. Impaired glucose transport across the BBB could contribute to this condition by 
acting as rate limiting factor [22], as suggested by autopsy studies showing reduced concentration of 
GLUT transporters in the microvasculature of the AD brain [23, 69, 70].  
Among possible causes of impaired glucose transport, it has been proposed that mitochondrial dys-
function in the BBB endothelium could play an important role [22, 71]. In addition, the ultrastructural 
alterations observed in capillary walls of the AD brain  [72–74] might – in principle – induce structur-
al alterations of transport proteins [75], thus hindering the active transport of nutrients across the 
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BBB. However, it is also possible that this putative transport defect does not lower intra-cerebral glu-
cose content to a sufficient extent to alter the metabolic rate [76, 77]. Furthermore, it remains unclear 
whether the hypothesised rate limiting effect of impaired transport could explain the early manifesta-
tion of hypometabolism observed in AD [78]. 
Taken together, the available evidence suggests, but does not prove, that impaired GLUT-dependent 
transport could contribute to the reduced glucose metabolism observed in AD, and this contribution 
could be aggravated by mitochondrial dysfunction and ultrastructural cellular damage.  
 
 2.2 Oxidative stress  
 
At low concentrations, reactive oxygen species (ROS) participate in the regulation of cell functioning 
by activating intracellular signalling cascades, whereas at higher concentrations ROS may cause oxi-
dative stress, a condition in which the production of ROS overcomes antioxidant defences [79], result-
ing in damage to lipids, proteins, and DNA [80].  
Oxidative stress is a feature of aging [81, 82], and age-related diseases [83], including AD [26, 84, 
85]. Due to its high rate of oxygen consumption, presence of redox-active metals and limited antioxi-
dant enzymatic defences, the brain is particularly vulnerable to oxidative damage [80, 86], and in-
creased levels of lipid peroxidation and nucleic acid oxidation are a consistent finding in the AD brain 
[72, 87]. 
Because Aβ plaques sequester redox-active metals [31], and Aβ deposits have been found in peri-
vascular cells and perivascular spaces surrounding cortical microvessels [72], it has been suggested 
that the cerebral microvasculature, and in particular the BBB, could actively contribute to the oxida-
tive injury observed in the AD brain. This view is supported by the highly reactive nature of the BBB 
endothelium, which is both a source of, and a target for, ROS and inflammatory proteins [18, 88]; and 
by the peculiar features of the ultrastructural damage in endothelial and perivascular cells, which is 
characterised by large lipid-laden vacuoles and damaged, swollen mitochondria [72]. Although a 
causative link between oxidative stress and microvascular damage has not been established in the AD 
brain in vivo, in vitro studies have shown that chronic oxidative stress increases BBB permeability, 
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promotes leukocyte adhesion, and alters endothelial signal transduction and redox-regulated transcrip-
tion factors [89]. 
Taken together, these data suggest that the dysfunctional BBB could actively foster the neurodegener-
ative process through separate (and possibly synergistic) pathways, by increasing the levels of ROS in 
the brain, by promoting the extravasation of monocytes and toxic molecules into the perivascular 
space, and by further reducing regional perfusion in a vicious circle.  
 
2.3 NO-mediated disruption of microvascular homeostasis  
 
NO is an important regulatory molecule with a fundamental role in neurovascular homeostasis. In en-
dothelial cells, NO regulates vascular tone, platelet aggregation, leukocyte adhesion, and endothelial 
junctional permeability [90–92]. NO is produced by three isoforms of NO synthase (NOS), endotheli-
al (eNOS), neuronal, and inducible (iNOS). The latter is induced (also in endothelial cells) by tran-
scription factors which are activated by cytokines during inflammation [93], and is capable of increas-
ing overall NO production, far beyond the levels produced by eNOS [94].  
A common feature of aging and cerebrovascular disease is the decrease of baseline endothelial NO 
synthesis [27]. Reduced endothelial NO production/bioavailability results in impaired vasodilation,  
reduced regional cerebral blood flow (CBF), and accumulation of oxidative stress, which are common 
features in AD [95]. There is evidence that pharmacological or genetic inactivation of eNOS in cul-
tured brain microvascular endothelial cells increase the expression of AβPP and β-site AβPP cleaving 
enzyme 1 (BACE-1), as well as Aβ production [96].  Consistently with these findings, other studies 
[97, 98] have shown an inverse correlation between eNOS-positive capillaries and Aβ senile plaques 
in cortical samples of AD brains. 
Chronic inhibition of constitutive NO production also increases endothelial permeability during in-
flammation [99]. Exposure of cultured human brain endothelial cells to cytokines (tumour necrosis 
factor (TNF)-α, interleukin (IL)-1β, interferon (IFN)-γ), decreased transendothelial electrical re-
sistance (TEER) and increased TJs permeability [99], which could be reverted by NO donors. 
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Constitutive endothelial NO is reduced in chronic hypoperfusion, as evidenced by reduced eNOS im-
munostaining in rat hippocampal capillaries following chronic bilateral carotid occlusion [100], with 
concomitant evidence of mitochondrial damage in endothelial and perivascular cells. These abnormal-
ities were associated with amyloid deposition surrounding the capillary wall, suggesting a possible 
interaction of the vascular damage with Aβ deposits. In addition, occluded rats (but not controls) 
showed worsened spatial memory following administration of eNOS inhibitors 8 weeks after occlu-
sion. These findings suggest that vascular NO derived from eNOS may play an important role in regu-
lating microvascular tone in the attempt to contrast the chronic reduction of CBF [100].  
Collectively, these data indicate that endothelial NO dysregulation may contribute to BBB dysfunc-
tion and permeability, oxidative stress, chronic regional hypoperfusion, and increased Aβ production. 
The effects of reduced endothelial NO could also be increased during inflammation and chronic hy-
poperfusion in a detrimental vicious circle, which could accelerate the neurodegenerative process in 
AD.   
 
2.4 Aβ-endothelium interaction 
 
2.4.1 Aβ trafficking and impaired Aβ clearance 
 
 
Aβ clearance from the brain is mediated by various mechanisms, such as glial phagocytosis, enzymat-
ic degradation, transport to the cerebrospinal fluid with subsequent re-absorption into the venous cir-
culation, and direct transport across the BBB [101].  
As macromolecules, Aβ peptides cross the BBB by active transport. The receptor for advanced gly-
cation end-products (RAGE) mediates Aβ transcytosis to the perivascular space (Aβ influx) [102, 
103], whereas Aβ efflux is mediated by multiple receptors, and in particular the lipoprotein receptor-
related protein 1 (LRP-1) [39, 104], and ATP binding cassette (ABC) subfamily B member 1, also 
termed P-glycoprotein (P-gp) [105–107]. Data from mouse models suggest that RAGE expression 
increases with age [108], whereas LRP-1 and P-gp decline [106], suggesting a possible path for in-
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creased Aβ deposition, and decreased clearance, respectively. P-gp expression was also found to in-
versely correlate with the deposition of Aβ1-40 and Aβ1-42 in elderly non-demented humans [109], indi-
cating a possible dose-dependent path for Aβ accumulation with increasing age. 
Due to the potential implication of impaired Aβ transport across the BBB on the development of AD, 
this topic has attracted substantial research effort. While some biopsy studies have shown increased 
Aβ influx mediated by RAGE upregulation in the human AD brain [55, 110, 111], reports from ani-
mal studies are conflicting. On the other hand, evidence of impaired Aβ efflux appears to be more 
consistent, with an implication of P-gp and LRP-1 transporters [39].  
Using PET imaging, P-gp function has been found to be reduced in AD patients [107], concomitant 
with increased Aβ deposition. This finding is consistent with a later in vitro study [112], in which Aβ1-
42 reduced P-gp expression in a murine BBB model. Interestingly, the Aβ-induced decrease of P-gp 
was attenuated when astrocytes were in close contact with endothelial cells, suggesting a protective 
role for astrocytes in preserving the expression of this transporter. As biopsy studies show morpholog-
ical alterations of endothelial cells, the question arises whether these changes could “detach” astro-
cytes from the basement membrane of the BBB endothelium, creating a favourable condition for the 
inhibition of Aβ efflux transporters. This hypothesis appears to be supported by the observation that 
the above morphological alterations precede the formation of perivascular Aβ deposits [113]. Con-
sistent with [112], another recent post mortem study [114] reported an inverse correlation between the 
burden of Aβ senile plaques and P-gp positive capillaries. 
Biopsy studies also suggest that Aβ alters LRP-1 activity [55, 111, 115]. Owen and colleagues [115] 
proposed that Aβ could impair its own efflux from the brain by oxidising LRP-1, thereby progressive-
ly inhibiting its vascular clearance pathway. A different view was presented by Wilhelmus and col-
leagues [116] who found that Aβ increased LRP-1 expression, and proposed that LRP-1 uptake of Aβ 
could ultimately saturate, resulting in Aβ accumulation. There is also evidence that BBB-mediated 
clearance of Aβ could be modulated by ApoE, in an isoform-dependent manner. Data from mouse 
models suggest that ApoE (especially ApoE-ε4) could divert Aβ efflux to slower receptors than LRP 
– such as the very low density lipoprotein receptor – ultimately resulting in Aβ accumulation [117].  
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Taken together, the above data indicate a possible pathway of BBB-mediated Aβ accumulation, pre-
dominantly based on reduced efflux rather than increased influx across the barrier. However, the in-
crease of influx transporters or decrease of efflux transporters only suggests a possible pathway of Aβ 
accumulation, it does not prove that the parenchymal accumulation of the peptide actually occurs be-
cause of this pathway [39], especially in vivo. Furthermore, it has recently been estimated that in the 
human brain, Aβ efflux across the BBB accounts for approximately 25% of the overall clearance of 
Aβ [118], whereas other pathways – including glial phagocytosis, proteolytic degradation, and 
transport to the cerebrospinal fluid with subsequent re-absorption into the venous blood [101, 119] – 
cumulatively account for the predominant proportion, suggesting that impaired BBB-mediated efflux 
might contribute to Aβ accumulation only marginally.  
 
2.4.2 Endothelium-mediated mechanisms of Aβ production 
 
It has been suggested that AβPP and Aβ observed in the perivascular space of the AD brain may be of 
endothelial origin [120, 121]. According to this hypothesis, altered expression of AβPP in endothelial 
cells could contribute to the accumulation of Aβ. Evidence from cultured endothelial cells suggests 
that thrombin could be implicated in this process by inducing AβPP secretion through both intracellu-
lar and cell surface pathways [122]. Prolonged endoplasmic reticulum (ER) stress could also induce 
intracellular AβPP accumulation and processing, leading to increased intracellular Aβ levels [123]. 
The possible effects of other stressors such as hypoxia, decreased glucose supply, and exposure to 
growth factors, on endothelial Aβ production have also been studied. Oxygen-glucose deprivation – 
an accepted model of ischemia [14, 124] – has recently been shown to increase Aβ1-42 production in 
the rat brain capillary endothelium through the upregulation of BACE-1 mediated by hypoxia induci-
ble factor 1α (HIF-1α) [120].  
It has been suggested that endothelial cells in the BBB could also contribute to Aβ production through 
the activity of enzymes which would cleave AβPP retained by circulating platelets (whose number is 
increased in AD), leading to the formation of Aβ fragments [39]. This hypothesis, however, appears to 
be supported by limited experimental evidence. 
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Collectively, these data suggest a potential active role of the BBB endothelium in the production of 
Aβ through proteolytic processing of AβPP. However, the extent to which this phenomenon could 
contribute to the parenchymal accumulation of the peptide and to the neurodegenerative process re-
mains to be established in vivo. 
 
2.4.3 Aβ-induced BBB permeability and transmigration of mononuclear cells   
 
Exposure of endothelial cells to Aβ induces morphological and biochemical alterations which affect 
BBB permeability. Deli and colleagues [125] reported Aβ1-42-induced ultrastructural changes in cul-
tured rat brain endothelial cells such as vacuolization, decreased number of caveolae and Golgi bod-
ies, and shrunken mitochondria. Irregular interendothelial junctions with fewer points of contact were 
also observed, with decreased TEER and increased paracellular permeability to fluorescein and albu-
min. TJ integrity in mouse endothelial cells was also regulated by ApoE [126], and Aβ1-42-RAGE in-
teraction [127, 128]. Some line of evidence also suggests that Aβ-induced BBB permeability might be 
mediated by protein kinase C (PKC), a family of enzymes involved in transmembrane signal transduc-
tion. PKC participates in the regulation of ion and water transport in the brain by stimulating the 
(Na+/K+)-ATPase pump [129], and has been indicated as potential mediator of BBB permeability [44]. 
Alterations in this enzyme have been reported in aging and dementia [130]. In AD, the activity of 
PKC and its isoforms is reduced in the cortex and hippocampus [131–134], and also in cerebral mi-
crovessels [44, 135]. Endothelial cells exposed to Aβ1–40, have shown PKC translocation from the 
plasma membrane to the intracellular domain (inactive state), suggesting that Aβ-endothelium interac-
tion might contribute to PKC inactivation [136] and, ultimately, BBB permeability. 
Aβ interaction with endothelial cells has also been shown to increase adherence and transmigration of 
monocytes across the BBB [43, 137, 138]. Transmigrated monocytes can then undergo differentiation 
into microglia [139], and become activated in inflammatory conditions.  
In vitro studies have identified potential mechanisms by which Aβ could promote endothelial adhe-
sion and transmigration of monocytes. Using a BBB model of human brain microvascular endothelial 
cells, Giri and colleagues [137] found Aβ1–40-induced monocyte transmigration to be inhibited by 
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RAGE and platelet endothelial cell adhesion molecule (PECAM-1) antibodies, which suggests a me-
diating role of the Aβ influx transporter. A subsequent study from the same group [43] showed in-
creased transmigration when the apical surface (luminal side) of the endothelium was exposed to Aβ1–
40, suggesting that cell polarity is another important factor.  
Aβ aggregation state has also been shown to play a role. Isolated soluble Aβ aggregates activated ad-
hesion and transmigration of monocytes, whereas un-aggregated monomers and mature fibrils did not 
[138]. A further study from the same group also demonstrated an implication of the nuclear factor-kB 
(NF-kB) in mediating Aβ-induced endothelial permeability to monocytes [140]. Aβ-induced BBB 
permeability to mononuclear cells has also been demonstrated in vivo. Farkas and colleagues [141] 
observed T-lymphocyte transmigration across the BBB after carotid infusion of Aβ25-35 in rats.  
In the perivascular space, the vasoactive agents and cytokines released by activated microglia can 
modify TJ assembly, further enhancing BBB permeability [34, 142] and the paracellular route for 
mononuclear cell extravasation [60]. This condition could trigger an “autotoxic” vicious circle in 
which the activation of microglia could cause neuronal damage, leading to further microglial activa-
tion [143, 144]. The latter effect appears to be sensitive to Aβ. Indeed, microglia exposed to Aβ1-42 
show increased expression of cytokines [145], suggesting that Aβ might exacerbate the effects of the 
vicious cycle.  
In the AD brain, activated microglia have been shown to co-localize with perivascular deposits of Aβ 
[146], suggesting a possible implication in the neurodegenerative process. While early accumulation 
of microglia seem to play a neuroprotective role by promoting Aβ clearance [147], data from mouse 
models suggest that this neuroprotective effect might be unable to cope with persistent Aβ accumula-
tion, especially in increasing age and progressing AD pathology [148], thus supporting the hypothesis 
that Aβ-induced monocyte transmigration could play a role in the neurodegenerative process. 
Taken together, these data corroborate the hypothesis that activated microglia could contribute to ex-
acerbating the inflammation-mediated neurodegenerative process of AD, especially under conditions 
of chronic inflammation and Aβ accumulation. 
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2.4.4 Vasoactive and apoptotic effects of Aβ  
 
Aβ has vasoactive effects on endothelial cells in vitro, which might contribute to reducing cerebral 
perfusion in AD. Deane and colleagues [102] observed reduced cortical CBF following infusion of 
Aβ1–40 in the mouse brain, which they showed to be Aβ-RAGE dependent and mediated by the upreg-
ulation of the vasoconstrictor endothelin-1 (ET-1). This vasoactive effect of Aβ was later confirmed 
by Palmer and colleagues [149] who reported Aβ1-40- and Aβ1-42-induced increases in ET-1 release in 
primary cultures of human brain endothelial cells.  
Aβ has also been shown to cause endothelial cell death in vitro [42, 46, 150]. Exposure of cerebral 
endothelial cells to elevated (micromolar) doses of Aβ1-40 caused mitochondrial dysfunction, nuclear 
and mitochondrial DNA damage, and cell death [46]. Consistent with these findings, a later study by 
Fonseca and colleagues showed the activation of ER stress-induced unfolded protein response (UPR) 
in rat brain endothelial cells incubated with Aβ1–40. UPR caused Ca2+ leakage from the ER store into 
the cytoplasm, and the activation of both mitochondria-dependent and independent apoptotic path-
ways [42]. A further study from the same group showed Aβ1–40-induced increases of nuclear HIF-1α, 
vascular endothelial growth factor (VEGF) and GLUT1, which correlated with oxidative stress mark-
ers [45]. Despite the above VEGF upregulation, several studies have shown the lack of angiogenesis 
[151–153], suggesting that in AD, Aβ-endothelial interaction could alter the ability of vessels to repair 
and regenerate after injury. 
Aβ has also been shown to dysregulate endothelial NO production [154, 155], possibly through the 
alteration of cytosolic Ca2+ homeostasis caused by Inositol 1,4,5-triphosphate (IP3) receptor leakage in 
the ER [154]. There is also evidence that the Aβ-induced reduction of NO bioavailability could be 
mediated by oxidative stress [156]. 
Collectively, the above in vitro evidence suggests that Aβ-endothelium interaction is able to disrupt 
intracellular Ca2+ homeostasis, with detrimental effects on NO synthesis, mitochondrial function, and 
ROS production, leading to accelerated cell senescence and death. These effects could in turn be ag-
gravated by a chronic state of hypoperfusion, such as resulting from sustained ET-1-mediated micro-
vascular vasoconstriction.      
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2.5 Endothelial response to chronic hypoperfusion-related hypoxia/ischemia 
  
Chronic regional hypoperfusion in the brain has been shown to compromise memory processes [14]. 
Substantial evidence from in vitro and biopsy studies also supports the hypothesis that chronic cere-
bral hypoperfusion plays an important role in the development of AD [7, 72, 75, 157–159]. Hy-
poperfusion-induced hypoxia evokes vascular responses, in which endothelial cells in the cerebral 
microcirculation play a central role. In vitro and biopsy studies have shown that hypoxia modulates 
endothelial junctional permeability, ROS generation [160, 161] and stimulates pro-inflammatory gene 
expression [18, 162]. 
The transcription factor HIF-1α is a key regulatory mediator of cellular responses to hypoxia, acting 
as sensor of low oxygen tension [18]. HIF-1α is elevated in the cerebral microcirculation of AD pa-
tients and AD mouse models [163, 164], and several studies have reported elevated inflammatory pro-
teins in brain endothelial cells exposed to hypoxia [18, 164], suggesting a link between hypoxia and 
cerebrovascular inflammation. This hypothesis is also supported by the work of Yamagata and col-
leagues [21] who reported a decrease in TEER of endothelial cells exposed to hypoxia, which was 
associated with IL-1β and NO. 
Hypoxia also affects AβPP processing and Aβ production [165], which could further contribute to the 
development of AD pathology. Acute hypoxia increased the expression and activity of BACE-1, re-
sulting in increased Aβ production [166]. Consistently with the above, exposure of cultured endothe-
lial cells to ischemia stimulated AβPP expression and cleavage into Aβ, resulting in increased Aβ 
production [167]. 
Hypoxia [21, 25, 168–170] and ischemia [171] have been shown to induce BBB permeability by alter-
ing the expression of junctional proteins. Importantly, the combined effect of hypoxia and aglycemia 
appears to enhance the increased BBB permeability produced by hypoxia alone [172].  
Hypoxia is also a potent stimulus for vascular activation and angiogenesis. Microvessels isolated from 
the brain of AD patients express a large number of angiogenic proteins, including VEGF [164], but 
without evidence of vascular growth [173]. The lack of vascular response could cause a chronic state 
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of activation of endothelial cells [174], resulting in the release of proinflammatory and potentially 
neurotoxic products. 
Hypoxia might also contribute to the low levels of mesenchyme homeobox 2 (MEOX-2) – a transcrip-
tion factor which regulates vascular cell differentiation and remodelling – which have been found in 
AD [175]. Downregulation of MEOX-2 in the AD brain endothelium have been shown to mediate an 
aberrant angiogenic response to VEGF resulting in vascular regression and reduced CBF [176]. Low 
levels of MEOX-2 also promote endothelial LRP degradation [176], thus favouring Aβ accumulation. 
Because of the anti-angiogenic effect of Aβ on brain endothelial cells [151, 153, 177], MEOX-2 
might mediate a cooperative effect of hypoxia and Aβ to induce vascular regression, ultimately lead-
ing to reduced regional CBF.  
Taken together, these data indicate multiple potential neurotoxic effects of chronic cerebral hy-
poperfusion, mediated by hypoxia/ischemia-induced activation of the BBB endothelium, resulting in 
Aβ production, expression of inflammatory proteins, BBB permeability, and vascular regression. The 
combined effects of hypoxia and aglycemia appear to cooperate in magnifying the endothelial re-
sponse. 
 
2.6 Microvascular endothelium as mediator of inflammatory processes 
  
Due to their critical role as regulators of cerebral homeostasis, perturbations of the microvascular en-
dothelium are closely linked to the pathophysiology of neuroinflammatory and neurodegenerative 
disease states, including AD [178–180]. 
Activated microglia and astrocytes are known endogenous sources of cytokines and chemokines in the 
AD brain [181]. However, increasing evidence shows that cerebral microvessels are also capable of 
expressing inflammatory mediators. Endothelial cells isolated from AD brains have revealed in-
creased expression of iNOS [94], and intercellular adhesion molecule-1 (ICAM-1) [182]. Non-
stimulated AD microvessels release higher levels of IL-1β, IL-6, TNF-α and transforming growth fac-
tor (TGF)-β compared to non-AD brains [181, 183]. In addition, cultured endothelial cells exposed to 
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oxidative stress have been shown to release thrombin [180], a neurotoxic protease which has been 
observed in cerebral microvessels [20] as well as senile plaques and NFT [184]. Thrombin, in turn, 
mediates the endothelial response to hypoxia by upregulating HIF-1α, inflammatory proteins (mono-
cyte chemoattractant protein (MCP)-1, IL-6), matrix metalloproteinase-2, and ROS [18]. Inflamma-
tion and hypoxia have also been shown to cooperate in mediating BBB permeability [21]. 
Collectively, these data suggest that the cerebral microvasculature could actively contribute to the in-
flammatory process observed in AD, contributing to the release of neurotoxic agents and increasing 
endothelial permeability. However, whether inflammation contributes to AD pathogenesis or it is a 
neurovascular response to the developing neurodegenerative process, remains unclear [6].  
 
2.7 Mitochondrial dysfunction and damage in BBB endothelial cells 
 
 
The ATP-dependent transport of macromolecules across the BBB requires efficient mitochondrial 
function for ATP production, which is reflected by the high number of mitochondria in endothelial 
cells of brain capillaries [9, 75]. However, data from autopsy studies of AD brains show reduced mi-
tochondrial density in the endothelium of cerebral capillaries [73, 74], as well as mitochondrial dam-
age – evidenced by broken cristae, membrane disruptions, swelling, and mitochondrial DNA dele-
tions – which co-localised with amyloid depositions and atherosclerotic lesions [72].  
Structural as well as functional mitochondrial alterations may result from different and possibly inter-
related causes, such as aging, oxidative stress, and Aβ toxicity.  
 
 
2.7.1 The effect of aging 
 
 
Aging – the main risk factor for sporadic AD [50, 185] – is a recognized cause of progressive mito-
chondrial damage [80, 186, 187]. Aging cells are affected by increasing oxidative stress and perturbed 
energy homeostasis [86, 187]. Mitochondria play a central role in this process as source of cellular 
energy (through the production of ATP), as major contributors to ROS production, and regulators of 
apoptosis [187]. Alterations of mitochondrial function are generally associated with an impaired elec-
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tron-transport chain [187–193]. Mutations of mitochondrial DNA (mtDNA) also accumulate with ad-
vancing age, possibly because of the proximity of mtDNA to the respiratory chain (the major site of 
oxidative stress), and a deficient mtDNA repair mechanism [187]. 
 
 
2.7.2 Effects of oxidative stress 
 
 
Chronic hypoperfusion causes glucose and oxygen deprivation. These conditions in turn lead to in-
creased ROS production through the disruption of the mitochondrial respiratory chain and subsequent 
depletion of ATP, elevation of matrix Ca2+ concentration, and release of cytochrome C [194]. 
Mitochondria, however, are not only sources of ROS and oxidative stress, but also a major target of 
oxidative damage. Lipids and proteins in the inner mitochondrial membrane are highly susceptible to 
ROS, and lipid peroxidation has been observed in oxidative injury [187, 195]. Damage to the inner 
membrane proteins and/or lipids can result in membrane depolarization and impaired mitochondrial 
function [82]. In the AD brain, oxidative injury has been demonstrated in mitochondria of neuronal 
[82, 187, 196], and also in vascular (endothelial) and perivascular cells [72, 89, 197]. Cellular energy 
failure is demonstrated in the AD brain by post mortem studies showing deterioration of mitochondri-
al ultrastructure, formation of non-mature mitochondria (“hypoxic mitochondria” [72, 89]) and exces-
sive mtDNA deletions [72, 195]. 
 
2.7.3 The effect of Aβ 
 
In addition to age and oxidative stress, structural and functional mitochondrial alterations may result 
from the interaction with soluble Aβ peptides [46, 198, 199], preceding the formation of Aβ plaques 
[200]. Aβ interaction with mitochondria has been shown to inhibit or reduce the activity of the res-
piratory chain complex III [201], complex IV [199–201], cause mtDNA damage [46], and activate 
apoptotic pathways [202]. Atamna and Frey [189] proposed a paradigm of Aβ-mediated mitochondri-
al dysfunction according to which Aβ would bind to heme and cause the loss of complex IV and sub-
sequent ATP deficit. According to this paradigm, due to its peroxidase activity the Aβ-heme complex 
21 
 
would cause oxidative damage to endothelial cells, contributing to endothelial dysfunction and ulti-
mately BBB disruption [189].  
 
 
2.7.4 Consequences of deficient ATP production 
 
 
Mitochondrial dysfunction results in deficient ATP production, which impairs ATP-dependent 
transport mechanisms in the plasma and ER membranes, such as the sodium (Na+/K+-ATPase) and 
calcium (Ca2+-ATPase) pumps [9, 203], and the ABC transporters [9]. Impaired Na+ and K+ homeo-
stasis in the perivascular space influences cell membrane depolarization in neurons, affecting neuronal 
and synaptic functions [9].  
Impaired sodium and calcium pump function results in the dysregulation of intracellular calcium con-
centration and signalling. This in turn affects endothelial NO synthase (eNOS) activity [204] and BBB 
permeability [203]. The deficient ATP production of dysfunctional mitochondria also leads to the 
dysregulation of ABC transporters, affecting brain supply of glucose and other nutrients, as well as 
Aβ clearance from the perivascular space [9]. ATP deficiency also results in the activation of apopto-
sis [187]. 
ATP deficiency, however, does not only affect transport (and ion flux) across the cell and ER mem-
branes. The ATP-sensitive potassium channels (mitoKATP) expressed in the mitochondrial membrane, 
are also affected in dysfunctional mitochondria. In the brain, mitoKATP are found at much greater con-
centrations than in cardiac myocytes, suggesting an important role of these channels in cerebral ho-
meostasis [194]. In normal conditions, the opening of mitoKATP causes a net influx of K+ into the mi-
tochondrial matrix, resulting in membrane depolarisation (which reduces the driving force for Ca2+-
uptake, thus opposing Ca2+ accumulation [205] and excessive ROS production [206, 207], with acute 
neuroprotective effect [207, 208]) and accelerated electron transfer in the respiratory chain, resulting 
in increased ATP production [194]. Preserving this mechanism through the administration of diazox-
ide – a mitoKATP channel opener – in conditions of chronic hypoperfusion or ischemia/reperfusion 
injury has been shown to protect neural function [194] and the BBB barrier function [209] in vivo. 
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Taken together, ATP deficit causes the alteration of many key elements of cellular homeostasis, re-
sulting in accelerated cell senescence and death. ATP deficit also impairs Aβ clearance and nutrient 
supply to the brain, thereby contributing to neuronal damage and AD progression. However, the ma-
jority of available quantitative data on mitochondrial dysfunction/damage relate to neuronal cells, and 
only relatively few studies have investigated the phenomenon in vascular cells in relation to AD.  
 
2.8 Endothelial interaction with pericytes 
 
Adjacent to the basement membrane of BBB endothelial cells are pericytes, multifunctional cells 
which contribute to structural stability, regulation of capillary blood flow, and clearance of toxic by-
products [210, 211]. Cross-talk signalling pathways between endothelial cells and pericytes have been 
identified [38, 210, 212], which regulate proliferation, migration, and recruitment of pericytes. In light 
of these findings, it has been hypothesised [63] that the location of pericytes along the microvascular 
tree could be determined functionally by the cross-talk with the adjacent endothelial cells. This hy-
pothesis is consistent with recent in vivo observations of adaptive plasticity of the cerebral microvas-
culature in the rat brain [213].  
Pericytes have typical properties of the contractile apparatus and their cell membrane expresses recep-
tors for multiple vasoactive mediators [38, 214–217]. The resting membrane potential of pericytes 
also appears to be regulated by similar mechanisms to those observed in vascular smooth muscle 
cells, with Ca2+-activated potassium channels, L-type voltage-dependent Ca2+ channels, agonist-
activated Ca2+ channels, and capacitative calcium entry [216]. Intracellular elevation of Ca2+  – a phe-
nomenon which in muscle cells precedes contraction – has also been observed in stimulated pericytes 
[215–217].  
At present, evidence of actual contraction is limited, and predominantly based on in vitro data. How-
ever, a recent study by Hall and colleagues [37] demonstrated that capillaries of anaesthetised mouse 
somatosensory cortex dilate in response to neuronal activity, as a result of pericyte relaxation. Dila-
tion of capillaries was found to precede that of the feeding arterioles, suggesting an active role of per-
icytes in the hyperaemic response. The authors hypothesised that the relaxation of pericytes could be 
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induced by prostaglandin E2 or a related compound, also involving NO production to contrast the 
synthesis of the vasoconstrictor 20-hydroxyeicosatetraenoic acid. Whether arterioles receive a signal 
to dilate from pericytes or from vasoactive messengers, remains to be elucidated. The study also 
showed that when exposed to ischemia, pericytes first caused vasoconstriction of capillaries then died 
in rigor. Although this would be expected to cause a long-lasting increase of the local resistance to 
flow, the latter was not measured in the above study. 
In summary, a potential role of pericytes in the regulation of regional CBF is starting to emerge, 
which could shed new light on microvascular dysregulation in pathological conditions in which 
chronic hypoperfusion and microvascular structural/functional damage are present. Although a link 
with AD has not been established [38], pericyte loss in mice overexpressing AβPP accelerates amy-
loid angiopathy, and pericyte deficiency leads to the development of tau pathology and early neuronal 
loss [210], suggesting a potential role of these scaffolding cells in AD development.  
 
2.9 Endothelial interaction with astrocytes 
 
Endothelial cells of the BBB are surrounded by perivascular astrocytic end-feet. In vitro evidence 
suggests that astrocytes may influence the BBB phenotype in the endothelium [218, 219]. Data from 
cultured cells demonstrate that astrocytes can modulate TJs (physical barrier) [34, 75, 220, 221], the 
expression and localization of transendothelial transporters, including P-gp and GLUT-1 among oth-
ers [34, 222]. Astrocytes also upregulate the expression of transferrin receptor and transcytotic mech-
anisms for low-density lipoproteins [223], and secrete TGF-β, glial-derived neurotrophic factor, basic 
fibroblast growth factor, and angiopoetin 1, which have been shown to induce aspects of the BBB 
phenotype in endothelial cells [34]. Furthermore, among agents modifying endothelial function and 
BBB permeability, several can be released by astrocytes, such as ET-1, glutamate, cytokines (IL-1β, 
IL-6, TNF-α), and macrophage inflammatory proteins [222]. 
While the above data support the hypothesis of an inductive influence of astrocytes on the endothelial 
phenotype in the BBB, reciprocal influences may also exist [34, 224]. The perivascular end-feet of 
astrocytes show several specialized features, including the water channel aquaporin 4 (AQP4) and the 
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inward rectifier (Kir4.1) K+ channel, which are involved in ion and volume regulation [34]. AQP4 co-
localizes with Kir4.1 and is segregated by agrin (a large proteoglycan in the basal lamina of the BBB 
endothelium) to the perivascular astrocytic end-feet [34], suggesting that the endothelium may con-
tribute to specialising the astrocytic phenotype [34]. 
Collectively, the above evidence suggests a complex interaction between astrocytes and BBB endo-
thelial cells, with potential implications in pathological conditions where the homeostatic function of 
the BBB is impaired. Indeed, astrocytes contribute to increase BBB permeability during inflammation 
by releasing inflammatory cytokines [34, 35], and in vitro astrocytes amplify the endothelial response 
to ischemia by increasing junctional permeability, and adhesion molecule expression [225]. Although 
these data suggest a possible implication of astrocyte-endothelium interaction in AD pathogenesis, 
this link has not been established. 
 
3. Microvascular innervation in the AD brain 
 
3.1 Intrinsic microvascular innervation and CBF regulation 
 
Cholinergic neurons of the basal forebrain and medial septum provide the major source of cholinergic 
intrinsic innervation to the cortex and hippocampus [226, 227]. The cholinergic cortical vasodilatation 
induced by stimulation of the basal forebrain is mediated by NO production, which is thought to re-
flect the activation of nitrergic interneurons and perivascular acetylcholine release [228].  Dysfunction 
of basal forebrain cholinergic neurons is a characteristic feature of AD [75, 228], which results in de-
nervation of cortical microvessels [229, 230], reduced expression of eNOS [231],  and reduced 
amount of nitrergic interneurons [230]. This condition likely compromises the ability of cortical per-
fusion to adapt to the increased metabolic demand caused by neuronal activation [229, 230], resulting 
in depressed CBF regulation, and ultimately, cerebral hypoperfusion. Experimental evidence supports 
the hypothesis that the basal forebrain can participate in neocortical CBF regulation, as it has been 
shown that unilateral lesions of the basal forebrain are followed by reduced ipsilateral CBF [75].  
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Taken together, the above data suggest that the loss of cortical cholinergic innervation might play a 
role in the regional CBF reduction observed in AD. However, it is unclear whether this phenomenon 
would contribute to the neurodegenerative process from an early stage (promoting a vicious circle), or 
only become manifest at advanced stages.    
 
3.2 Microvascular adrenergic innervation and BBB permeability 
 
Adrenergic receptors exist in brain microvessels, with a predominance of β receptors [232–237]. In-
creased levels of β2 and α2 adrenoceptors have been reported in AD [237], suggesting possible altera-
tions of the extrinsic regulation of the microvascular tone, which might contribute to impairing re-
gional CBF distribution. Because microvascular noradrenergic innervation in cerebral microvessels 
also participates in the regulation of the (Na+/K+)-pump  [238] (an important feature of the BBB func-
tion which regulates water and electrolyte homeostasis) it could be hypothesised that alteration of 
noradrenergic innervation could also alter fluid exchange at the BBB, thus creating another potential 
pathway of impaired CBF distribution. However, quantitative evidence is needed to confront this hy-
pothesis.  
 
4. Microvascular ultrastructural alterations in the AD brain 
 
Substantial evidence from post mortem biopsy studies shows ultrastructural alterations in cerebral mi-
crovessels of the cortex of the AD brain [74, 75, 239, 240], which appear to co-localise with regions 
of Aβ deposits [72]. Kalaria and Hedera [240] found capillaries with collapsed or degenerated endo-
thelium in AD, which were almost absent in brain regions free of Aβ deposits and in control subjects. 
Another study from the same group [239] reported an increased content of collagen IV – the main 
constituent of the basement membrane – in microvessels of AD brains compared to age-matched con-
trols. This finding is consistent with the work of Farkas and colleagues [241] who observed a thick-
ened basement membrane and collagen accumulation in cortical microvessels of AD brains. Similar 
findings were described by Claudio [73], who additionally reported an inverse correlation between 
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endothelial pinocytotic vesicle concentration and mitochondrial concentration. Evidence of increased 
size/concentration of endothelial vesicles in AD has also been reported in other studies [72, 75]. Con-
sistent with Claudio [73], Stewart and colleagues observed a reduced density of mitochondria in the 
cerebral capillary endothelium of AD patients [74]. The study also reported an increased number of 
capillaries containing pericytes, which the authors interpreted as a protective scaffold to support the 
weak endothelium which showed junctional leakiness. An interesting view proposed by Broadwell 
and Salcman [242] is that pericytes could also limit the damage of a leaky BBB by acting as 
macrophages, degrading extravasated serum proteins in their lysosomes.  
Aliev and colleagues observed heterogeneous lesions in endothelial cells of cerebral microvessels of 
AD brains (and transgenic mice overexpressing AβPP), which were absent in age-matched controls 
[72, 89, 113, 197]. These vascular abnormalities included clusters of mitochondria-derived lysosomes, 
large-sized lipid vacuoles, and necrotic structures. Interestingly, in early AD samples without ultra-
structural damage, the luminal side of endothelial cells protruded into the vessel lumen, suggesting 
that the effects of hypoperfusion might precede ultrastructural damage [89]. Furthermore, the ultra-
structural abnormalities of the vascular wall cells co-localised with Aβ deposits around the mi-
crovessels [72, 89, 197]. Immunocytochemical analyses also revealed the presence of atherosclerotic 
lesions and mtDNA deletions in the damaged vascular wall, which were accompanied by increased 
AβPP and oxidative stress markers [89]. These vascular abnormalities were associated with the selec-
tive damage to cortical neurons [89, 197], suggesting that chronic hypoperfusion might be a primary 
cause of the accumulation of oxidative injury products [95], which would initiate the process of neu-
rodegeneration. This hypothesis appears to be supported by the notion that oxidative stress is an early 
event in AD pathogenesis [72, 87, 243]. 
 
5. Network of causative relationships 
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Cerebral hypoperfusion and BBB dysfunction are key elements in the vascular pathway to AD. In 
vitro findings supports the hypothesis that factors resulting from cerebral hypoperfusion and BBB 
dysfunction are also potential causing factors, suggesting the existence of detrimental vicious circles.  
The complex interconnections of endothelium-mediated mechanisms reviewed in previous sections 
are synthesised here in the form of a network of causative relationships linking the above mechanisms 
(Figure 1).  
 
5.1. Chronic cerebral hypoperfusion 
 
 
Aging (the main risk factor for sporadic AD [50, 185]), vascular conditions [6, 8–11], and possibly 
cardiac conditions [7, 12, 13] cause chronic cerebral hypoperfusion. This in turn reduces oxygen and 
energy supply to the brain tissue [14], ultimately leading to neuronal damage.  
Hypoperfusion also damages the BBB and is aggravated by vasogenic oedema such as caused by per-
icyte detachment [9] or vascular cell death. Basal forebrain cholinergic deficit (a characteristic feature 
of AD [75, 228]) results in denervation of cortical microvessels [229, 230], further impairing CBF 
distribution. Hypoperfusion is also aggravated by the ischemia-induced death of pericytes [37], which 
constrict in rigor before dying, increasing resistance to microvascular flow.  
Indirect effects of chronic hypoperfusion such as oxidative stress, inflammation and mitochondrial 
dysfunction, cause BBB permeability and structural damage to the microvascular wall [72]. These 
effects could mediate vicious circles, which could aggravate regional CBF reduction (and reduction of 
oxygen/glucose supply to the brain), ultimately accelerating the neurodegenerative process. 
 
5.2 Hypoxia/ischemia 
 
 
Hypoxia induces BBB permeability [21, 25, 168–170], ROS generation [160, 161] and stimulates pro-
inflammatory gene expression [18, 162]. Hypoxia and inflammation may cooperate in inducing BBB 
permeability [21]. Likewise, aglycemia aggravates BBB permeability induced by hypoxia [172]. 
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Hypoxia/ischemia affect AβPP processing and Aβ production [165–167]. Hypoxia also stimulates 
endothelial angiogenic proteins, including VEGF [164]. However, the lack of vascular growth in re-
sponse to VEGF [173] might cause a chronic state of endothelial activation, resulting in the release of 
proinflammatory and potentially neurotoxic products. Hypoxia is also associated with low levels of 
MEOX-2 in AD, resulting in degradation of endothelial LRP-1, regression of capillary networks, and 
reduced cerebral microcirculation [175, 176]. Reduced LRP-1 promotes perivascular accumulation of 
Aβ. Because of the anti-angiogenic effect of Aβ [151, 153, 177], there may be a cooperative effect of 
hypoxia and Aβ to induce vascular regression and subsequent reduction of regional CBF, in a vicious 
circle. 
Ischemia causes pericyte death and detachment [37]. The detachment of pericytes causes leakage of 
serum proteins and focal microhaemorrhages [9], resulting in vasogenic oedema [9], further contrib-
uting to hypoperfusion and hypoxia of the surrounding parenchyma, thus aggravating neuronal injury. 
Pericyte death in rigor causes a restriction of the capillary lumen [37], with increased resistance to 
flow and consequent reduction of regional CBF. 
 
5.3 Oxidative stress 
 
 
Excessive ROS and RNS production in oxidative stress causes scavenging of NO (e.g. by sequestra-
tion into peroxynitrite), with subsequent reduction of NO bioavailability [244]. Oxidative stress also 
damages mitochondria [82, 86]. Because mitochondria are a major source of ROS and dysfunctional 
mitochondria can increase ROS production [196], this might lead to a vicious circle which could ag-
gravate BBB damage.  
Oxidative stress also decreases the expression of LRP-1 and upregulates RAGE,  potentially leading 
to increased perivascular Aβ deposition [15]. Furthermore, oxidative stress increases BBB permeabil-
ity, promotes leukocyte adhesion [89], and endothelial release of the neurotoxic protease thrombin 
[180]. 
 
5.4 Inflammation 
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Endothelial cells isolated from AD brains release inflammatory proteins [94, 181–183]. Inflammation 
enhances the endothelial response to hypoxia increasing BBB permeability. Astrocytes also contribute 
to BBB permeability during inflammation by releasing inflammatory cytokines [34, 35]. 
 
5.5 Mitochondrial dysfunction 
 
 
Glucose and oxygen deprivation caused by chronic hypoperfusion [194], oxidative stress [82, 86], and 
Aβ [46, 189, 198–202] contribute to the dysregulation of mitochondrial function. This in turn depletes 
ATP stores, impairs ATP-dependent transport (of ions and Aβ), and increases intracellular Ca2+ con-
centration, disrupting vital signalling pathways, and leading to apoptosis  [9, 203]. Dysfunctional mi-
tochondria also increase ROS production and oxidative damage in a vicious circle. 
 
 
5.6 Aβ-endothelium interaction 
 
 
Aβ efflux transporters P-gp and LRP-1 decrease in AD [107, 115], suggesting a possible pathway to 
perivascular Aβ accumulation. However, this contribution is likely marginal [118]. 
Aβ dysregulates endothelial NO production [154, 155], possibly through the alteration of cytosolic 
Ca2+ homeostasis [154]. Aβ-induced reduction of NO bioavailability might also be mediated by oxida-
tive stress [156]. Inactivation of eNOS increases the expression of AβPP and BACE-1, as well as Aβ 
production [96], potentially sustaining a vicious circle. Reduced endothelial NO produc-
tion/bioavailability in turn impairs regional CBF [100]. 
Aβ-endothelium interaction induces BBB permeability [125–128], possibly mediated by PKC inacti-
vation [136]. Aβ also increases adherence and transmigration of monocytes across the BBB [43, 137, 
138], mediated by the transcription factor NF-kB [140]. Transmigrated monocytes undergo differenti-
ation into microglia [139], and become activated in inflammatory conditions. The vasoactive agents 
and cytokines released by activated microglia can in turn induce BBB permeability [34, 142], creating 
a paracellular route for mononuclear cell extravasation [60], in a vicious circle.  
30 
 
Furthermore, Aβ induces vasoconstrictor ET-1 release [102, 149] – thus reducing regional CBF [102] 
– and activates the endothelial inflammatory response [245, 246]. Finally, at high concentrations Aβ 
causes endothelial apoptosis [42, 46, 150] by disrupting intracellular Ca2+ homeostasis.  
 
5.7 BBB permeability 
 
BBB permeability is influenced by hypoxia/ischemia [21, 25, 168–170, 172], inflammation [19], oxi-
dative stress  [15], and Aβ [125–128]. Astrocytes also contribute to BBB permeability during inflam-
mation by releasing inflammatory cytokines [34, 35], and amplify the endothelial response to ische-
mia by increasing junctional permeability [225]. 
Alterations of the adrenergic microvascular innervation might alter the (Na+/K+)-pump function of the 
BBB, possibly resulting in fluid balance impairment [238] and dysregulation of regional CBF.  
 
6. Conclusions 
 
Based on the current literature on endothelium-mediated mechanisms underlying vascular dysfunction 
in AD pathogenesis, this study has presented a comprehensive overview of the complex network of 
the interacting mechanisms, with particular emphasis on causative relationships, and mediators of det-
rimental vicious circles, such as hypoxia/ischemia, oxidative stress, inflammation and mitochondrial 
dysfunction. The possible implication of other components of the BBB, such as pericytes and astro-
cytes, in this complex scenario has also been investigated. 
As new mechanisms are discovered in this rapidly evolving field of research, the proposed network 
can be expanded, adding new elements (mechanisms) and/or interactions. Prospectively, this network 
could be exploited in the identification of adequate therapeutic interventions to treat, delay or prevent 
AD.   
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Figure Captions 
 
 
Figure 1. Causative relationships of endothelium-mediated mechanisms of vascular dysfunction 
in AD pathogenesis. Green boxes indicate systemic factors causing regional cerebral hypoperfusion, 
orange boxes indicate key mediators of vicious circles leading to hypoperfusion aggravation. Arrows 
indicate causal relationship in the direction of the arrow. Arrows pointing up inside a box indicate 
upregulation/increased quantity; arrows pointing down indicate the opposite. See text for further de-
tail. ABC: ATP binding cassette (transporter); Aβ: amyloid-β; AβPP: Aβ precursor protein; BACE-1: 
β-site AβPP Cleaving Enzyme 1; BBB: blood-brain barrier; BF: basal forebrain; ER: endoplasmic 
reticulum; LRP-1: low-density lipoprotein receptor-related protein 1; MEOX-2: mesenchyme homeo-
box gene-2; NO: nitric oxide; PKC: protein kinase C; P-gp: P glycoprotein; RAGE: receptor for ad-
vanced glycation end-products; RNS: reactive nitrogen species; ROS: reactive oxygen species; TEER: 
Transendothelial resistance; VEGF: vascular endothelial growth factor. 
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